Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults.

Tianyu SunLinwei LiKatherine E MuesMihaela V GeorgievaBrenna KirkJames A MansiNicolas Van de VeldeEkkehard C Beck

Published in: Infectious diseases and therapy (2024)

Our findings suggest a third dose of mRNA-1273 is more effective than a third dose of BNT162b2 in preventing COVID-19 hospitalization and breakthrough medically attended COVID-19 among IC adults in the US.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial

systematic review
respiratory syndrome coronavirus

palliative care
mental health

extracorporeal membrane oxygenation
mechanical ventilation